GGrantIndex
← Search

Cancer Epidemiology

$73,302P30FY2024CANIH

University Of Southern California, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07456436Trial NCT07339254Trial NCT07332312Trial NCT07312162Trial NCT07306338Trial NCT07279571Trial NCT07276048Trial NCT07259304Trial NCT07229443Trial NCT07186699Trial NCT07162194Trial NCT07082257Trial NCT07076147Trial NCT06500169Trial NCT06422455Trial NCT06420219Trial NCT06374251Trial NCT06338657Trial NCT06336928Trial NCT06336902Trial NCT06297265Trial NCT06191575Trial NCT06171607Trial NCT06132087Trial NCT06128525Trial NCT06067295Trial NCT06063928Trial NCT06063486Trial NCT06060873Trial NCT05989828Trial NCT05791448Trial NCT05786664Trial NCT05516485Trial NCT05514990Trial NCT05462561Trial NCT05340309Trial NCT04981834Trial NCT04941430Trial NCT04927559Trial NCT04832763Trial NCT04830735Trial NCT04752267Trial NCT04387084Trial NCT04387071Trial NCT04373044Trial NCT04318028Trial NCT04315701Trial NCT04162678Trial NCT03971266Trial NCT03921047Trial NCT03858205Trial NCT03789773Trial NCT03739801Trial NCT03698162Trial NCT03657641Trial NCT03594448Trial NCT03576963Trial NCT03568292Trial NCT03568266Trial NCT03563651Trial NCT03563352Trial NCT03552796Trial NCT03537690Trial NCT03519984Trial NCT03514927Trial NCT03492801Trial NCT03485794Trial NCT03412370Trial NCT03408561Trial NCT03353896Trial NCT03348137Trial NCT03344211Trial NCT03330821Trial NCT03300609Trial NCT03300401Trial NCT03284346Trial NCT03267680Trial NCT03257761Trial NCT03238664Trial NCT03234556Trial NCT03207854Trial NCT03176979Trial NCT03146871Trial NCT03137706Trial NCT03120390Trial NCT03111823Trial NCT03098277Trial NCT03092856Trial NCT03091842Trial NCT03091816Trial NCT03091803Trial NCT03057639Trial NCT03049618Trial NCT03042897Trial NCT02978846Trial NCT02970617Trial NCT02970045Trial NCT02968680Trial NCT02967380Trial NCT02960308

Abstract

PROJECT SUMMARY – Cancer Epidemiology (CE) Program The mission of the Cancer Epidemiology (CE) Program is to investigate the determinants of cancer risk and progression through epidemiological studies strongly grounded in the relevant biology. The program also includes the development of novel biostatistical approaches that incorporate complex biological measures from population-based studies to elucidate mechanisms and pathways. The CE program is led by Christopher Haiman ScD, a cancer and genetic epidemiologist whose research is focused on genetic risk of prostate and breast cancer, and V. Wendy Setiawan PhD, an expert on cancer risk factors, disparities, and big data linkages whose research focuses on liver, pancreas and endometrial cancer. The program has 25 members who collaborate within CE and throughout NCCC to accomplish three Specific Aims: 1) Elucidate the role of genetic factors in cancer etiology and outcomes with emphasis on different racial/ethnic populations; 2) Elucidate the role of environmental and lifestyle factors in cancer etiology; and 3) Develop and apply methods for integrative statistical analysis of ‘omics’ data in environmental and genetic epidemiology research in cancer. During this funding cycle, CE members made major novel discoveries including: 1) identification of potentially carcinogenic molecular signatures in e-cigarette users; 2) elevated risk of pancreatic cancer among individuals with late-onset diabetes in African Americans and Latinos; 3) cytomegalovirus as a novel risk factor for acute lymphoblastic leukemia (ALL) and multiple myeloma (MM); 4) demonstration that exposure to air pollution is a risk factor for breast and brain cancer and is associated with decreased survival; 5) development of a multiethnic polygenic risk score for prostate cancer that is being translated to a clinical study with collaborators in the TACS Program; and 6) identification of disparities in prevalence of non-alcoholic fatty liver disease and its role as risk factor for liver cancer among minority populations. Through effective evaluation and planning, CE established new Program goals, catalyzed intra- and inter-programmatic collaborations, and fostered effective junior faculty mentorship. During the current grant period, CE investigators published 607 papers, of which 33% are intra- programmatic, 20% are inter-programmatic, 76% are multi-institutional, and 26% are high impact (IF >9). Members hold $13.5M in cancer-relevant funding, of which $12.2M is peer reviewed and $6.4M is NCI funding (directs). The CE Program contributes critically to NCCC’s mission of decreasing the cancer burden in the catchment area through knowledge of etiologic risk factors underlying cancer disparities.

View original record on NIH RePORTER →